Published in Oncotarget on September 13, 2016
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res (2007) 2.95
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol (1996) 2.83
Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell (2009) 2.76
Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol (2006) 2.59
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature (2008) 2.51
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res (2001) 2.50
The AP-2 family of transcription factors. Genome Biol (2005) 2.46
Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev (2010) 2.06
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A (2013) 2.02
The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci U S A (1995) 1.76
Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol (1999) 1.66
Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol (2007) 1.65
Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2004) 1.56
The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein. J Biochem (2007) 1.55
The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause (2011) 1.52
AP-2γ regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J (2011) 1.49
Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci U S A (1992) 1.48
Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2004) 1.47
Activator protein-2 in carcinogenesis with a special reference to breast cancer--a mini review. Int J Cancer (2007) 1.42
Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol (1996) 1.36
Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer (2003) 1.35
Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res (2001) 1.34
Identification of ERF-1 as a member of the AP2 transcription factor family. Proc Natl Acad Sci U S A (1997) 1.31
Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res (1993) 1.27
Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors. Clin Cancer Res (2004) 1.27
Genes preferentially expressed in embryo stomach are predominantly expressed in gastric cancer. Cancer Res (1992) 1.24
Transcription factor AP-2gamma stimulates proliferation and apoptosis and impairs differentiation in a transgenic model. Mol Cancer Res (2003) 1.21
Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. Prostate (1999) 1.20
Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol (2008) 1.19
Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer. Mol Cancer (2013) 1.17
The Ishikawa cells from birth to the present. Hum Cell (2002) 1.17
Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol (1988) 1.16
Characterization of the proximal estrogen-responsive element of human cathepsin D gene. Mol Endocrinol (1994) 1.14
NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene (2008) 1.11
Nucleophosmin acts as a novel AP2alpha-binding transcriptional corepressor during cell differentiation. EMBO Rep (2007) 1.10
Induction of immune responses to ovarian tumor antigens by multiparity. J Soc Gynecol Investig (1998) 1.10
Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation. Mol Cell Proteomics (2010) 1.06
Differential regulation of estrogen receptor α expression in breast cancer cells by metastasis-associated protein 1. Cancer Res (2014) 1.01
Transcription factor AP-2gamma, a novel marker of gonocytes and seminomatous germ cell tumors. Int J Cancer (2005) 1.00
Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology (2004) 0.98
EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine-immune interactions. Br J Cancer (2001) 0.97
AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene. EMBO J (2009) 0.97
Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev (2010) 0.97
Nkx3-1 and LEF-1 function as transcriptional inhibitors of estrogen receptor activity. Cancer Res (2008) 0.96
Genomic structure of the promoters of the human estrogen receptor-alpha gene demonstrate changes in chromatin structure induced by AP2gamma. J Biol Chem (2001) 0.95
Genome-wide activity of unliganded estrogen receptor-α in breast cancer cells. Proc Natl Acad Sci U S A (2014) 0.95
Dephosphorylation of nucleophosmin by PP1β facilitates pRB binding and consequent E2F1-dependent DNA repair. Mol Biol Cell (2010) 0.93
Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5'-untranslated region. Biochem J (2004) 0.90
17Beta-estradiol suppresses TLR3-induced cytokine and chemokine production in endometrial epithelial cells. Reprod Biol Endocrinol (2005) 0.90
Nucleophosmin/B23 regulates transcriptional activation of E2F1 via modulating the promoter binding of NF-kappaB, E2F1 and pRB. Cell Signal (2006) 0.89
Fertility-preserving treatment in young women with endometrial adenocarcinoma: a long-term cohort study. Int J Gynecol Cancer (2014) 0.88
Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol (1985) 0.87
Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. Acta Oncol (1989) 0.86
Nucleophosmin is overexpressed in thyroid tumors. Biochem Biophys Res Commun (2010) 0.86
Epigenetic modification restores functional PR expression in endometrial cancer cells. Curr Pharm Des (2014) 0.86
Estrogen stimulates the proliferation of human endometrial cancer cells by stabilizing nucleophosmin/B23 (NPM/B23). J Mol Med (Berl) (2012) 0.83
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol (2005) 0.81
Infiltrating Macrophages Induce ERα Expression through an IL17A-mediated Epigenetic Mechanism to Sensitize Endometrial Cancer Cells to Estrogen. Cancer Res (2016) 0.81
Membrane progesterone receptor alpha as a potential prognostic biomarker for breast cancer survival: a retrospective study. PLoS One (2012) 0.81
Expression of pS2 protein in endometrial carcinomas: correlation with clinicopathologic features and sex steroid receptor status. Int J Cancer (1997) 0.78
Features associated with survival and disease-free survival in early endometrial cancer. Am J Obstet Gynecol (1989) 0.78
Successful pregnancy after tamoxifen and megestrol acetate therapy for endometrial carcinoma. Br J Obstet Gynaecol (1994) 0.78
Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study. J Reprod Med (2014) 0.78
Can probability of genetic mutation be an indicator of clinical relevance? Genomics (2007) 0.76
Breast cancer: relevance of estrogen receptor determination at relapse. J Clin Oncol (1997) 0.76